A Phase 1/2 interventional study of Phase1 and Phase 2: decitabine and Phase 1: cytarabine in Acute Myeloid Leukemia, sponsored by Janssen Research & Development, LLC. Terminated at 17 sites in 7 countries. Open to participants aged 1 Month to 18 Years. Per ClinicalTrials.gov, last updated 2019-06-17.
Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 121 studies testing decitabine in Leukemia, Myeloid, Acute — 20 open to participants now, 33 under way, 2 of them phase 3. Decitabine · Leukemia, Myeloid, Acute.
Among the 121 studies testing decitabine in Leukemia, Myeloid, Acute, this one is the 87th largest by enrollment of the 120 interventional ones that give a count, is one of 9 that started in 2013, is one of 15 in phase 1/2, and was the 46th registered.
3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 817 are open to participants now.
Browse Leukemia, Myeloid, Acute studies →20 of the 121 studies testing decitabine in Leukemia, Myeloid, Acute are open now, in 5 countries. Recruiting first, the newest first:
PETHEMA Foundation · Sites in Portugal, Spain
Ages 18+
National Cancer Institute (NCI) · Sites in United States
Ages up to 21
The Methodist Hospital Research Institute · Sites in United States
Ages 18+
David Avigan · Sites in United States
Fred Hutchinson Cancer Center · Sites in United States
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
Decitabine: first FDA approval 2006 (DACOGEN), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.
This study: 1 Month to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
121 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 52 · Phase 2 72 · Phase 3 13 · Phase 4 2
First in 1995; this study’s year is marked. 9 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 17 is below the median of 40 across 3,007 interventional studies indexed under Leukemia, Myeloid, Acute.
Median enrollment 32 across the 120 interventional studies. Of the 67 that completed or were terminated, 39 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 121 have an industry lead sponsor. The 10 most frequent:
This study is registered under Janssen Research & Development, LLC, one of the names counted as Johnson & Johnson. Under that name alone:
Janssen Research & Development, LLC is the lead sponsor of 932 studies on the registry; 76 are open to participants now.
Of its 285 completed or terminated interventional studies of FDA-regulated products, 137 (48%) have results posted.
15 studies in Leukemia, Myeloid, Acute by Johnson & Johnson: 2 open now, 4 under way, 1 of them phase 3. Of 10 finished, 2 (20%) have results posted.
Among the 15 studies in Leukemia, Myeloid, Acute by Johnson & Johnson, this one is the 13th largest by enrollment, is the only one that started in 2013, is the only one in phase 1/2, and was the 4th registered.
Johnson & Johnson’s Leukemia, Myeloid, Acute studies by the year they started, since 2001.
6 of the studies testing decitabine in Leukemia, Myeloid, Acute that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06129734Benjamin TomlinsonDecitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell Transplant | 2027-03 |
| NCT05190471Bio-Path Holdings, Inc.A Clinical Trial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML) | 2027-03 |
| NCT05222984City of Hope Medical CenterNavitoclax, Venetoclax, and Decitabine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Previously Treated With Venetoclax | 2027-03-02 |
| NCT07012044National Cancer Institute (NCI)A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia | 2027-03-31 |
| NCT07374029David AviganAdoptive T Cell Therapy With DC/AML Fusion Vaccine Plus Decitabine and Venetoclax in AML | 2027-10-01 |
Add all 6 to your calendar (.ics) → With an account.
Among the 121 studies testing decitabine in Leukemia, Myeloid, Acute, from their registry updates:
Among Johnson & Johnson’s 15 in Leukemia, Myeloid, Acute:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to examine the safety and efficacy of decitabine in sequential administration with cytarabine in children with relapsed or refractory acute myeloid leukemia (AML).
This is an open-label (identity of assigned study drug will be known) study to evaluate safety, efficacy, and pharmacokinetics (study of what the body does to a drug) of decitabine in sequential administration with cytarabine in children with relapsed or refractory AML. The study will determine the maximum tolerated dose of cytarabine that can be given following decitabine (Phase 1) and the response rate to this combination (Phase 2). Participants may enter a continuation phase of single agent-decitabine infusions for as long as such treatment would be considered beneficial. Serial pharmacokinetic samples will be collected and safety and efficacy will be monitored throughout the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Phase1 and Phase 2: decitabine · Drug: Phase 1: cytarabine · Drug: Phase 2: cytarabine
Drug page: Decitabine
20 mg/m2 administered by intravenous infusion over 1 hour once daily for 5 consecutive days (Day 1 to Day 5 of 28-day cycle)
1 g/m2, 2 g/m2, and 1.5 g/m2 dose levels administered by intravenous infusion over 4 hours daily for 5 consecutive days (Day 8 to Day 12 of 28-day cycle) for the determination of the maximum tolerated dose
Phase 1 maximum tolerated dose administered by intravenous infusion over 4 hours daily for 5 consecutive days (Day 8 to Day 12 of 28-day cycle)
Phase 1: Maximum Tolerated Dose (MTD) of Cytarabine
The maximum tolerated dose (MTD) for cytarabine was based on the number of participants experiencing a dose-limiting toxicity (DLT) by the end of Cycle 1. A non-hematological DLT was defined as: any Grade \>=3 toxicity that persists for greater than (\>) 5 days or any Grade 2 toxicity that persists for \>7 days and that is intolerable to the participant. A hematological DLT was defined as Grade 4 neutropenia or thrombocytopenia due to a hypoplastic bone marrow at Day 42, in the absence of malignant infiltration. The nominal duration of each cycle was 28 days. However, participants who had not experienced bone marrow recovery at Day 28 were followed up to Day 42. Failure of marrow recovery (improvement to Grade 3) by Day 42 was considered a DLT. The maximum duration of Cycle 1 was therefore 42 days.
Time frame: Cycle 1 (42 days)
Phase 1 and 2: Total Clearance of Decitabine
Total clearance of drug after intravenously administration was calculated as: dose/area under the plasma concentration-time curve.
Time frame: Cycle 1 (28 days) Day 5: pre-infusion, 0.5 hour during infusion, end of infusion and at 5 minute (min), 0.5 hour, 1 hour, and 2 hour after end of infusion
Phase 1 and 2: Volume of Distribution at Steady-State (Vss) of Decitabine
Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug.
Time frame: Cycle 1 (28 days) Day 5: pre-infusion, 0.5 hour during infusion, end of infusion and at 5 min, 0.5 hour, 1 hour, and 2 hour after end of infusion
Phase 2: Percentage of Participants Who Achieved CR or CRi at Cycle 1 Day 28
Response rate (percentage of participants who achieved CR or CRi) was measured using international working group (IWG) criteria. Response rate is defined as complete remission (CR) or complete remission with incomplete blood count recovery (CRi) in children with relapsed or refractory acute myeloid leukemia. CRi is defined as morphologic CR with residual neutropenia (less than \[\<\] 1,000/microliter) or thrombocytopenia \<100,000/ microliter). CR is defined as morphologic leukemia-free state, with less than 5 percentage (%) blasts in aspirate sample with marrow spicules and with a count of greater than or equal to (\>=) 200 nucleated cells, plus absolute neutrophil count (ANC) greater than (\>) 1,000/ microliter, platelet count of \>100,000/microliter and participant must be independent of transfusions for a minimum of 1 week before each marrow assessment.
Time frame: Cycle 1 (28 days) Day 28
Phase 2: Percentage of Participants Who Achieved CR or CRi at Cycle 2 Day 28
Response rate (percentage of participants who achieved CR or CRi) was measured using international working group (IWG) criteria. Response rate is defined as complete remission (CR) or complete remission with incomplete blood count recovery (CRi) in children with relapsed or refractory acute myeloid leukemia. CRi is defined as morphologic CR with residual neutropenia (less than \[\<\] 1,000/microliter) or thrombocytopenia \<100,000/ microliter). CR is defined as morphologic leukemia-free state, with less than 5 percentage (%) blasts in aspirate sample with marrow spicules and with a count of greater than or equal to (\>=) 200 nucleated cells, plus absolute neutrophil count (ANC) greater than (\>) 1,000/ microliter, platelet count of \>100,000/microliter and participant must be independent of transfusions for a minimum of 1 week before each marrow assessment.
Time frame: Cycle 2 (28 days) Day 28
Phase 2: Percentage of Participants Who Achieved CR or CRi at End of Study Treatment
Response rate (percentage of participants who achieved CR or CRi) was measured using international working group (IWG) criteria. Response rate is defined as complete remission (CR) or complete remission with incomplete blood count recovery (CRi) in children with relapsed or refractory acute myeloid leukemia. CRi is defined as morphologic CR with residual neutropenia (less than \[\<\] 1,000/microliter) or thrombocytopenia \<100,000/ microliter). CR is defined as morphologic leukemia-free state, with less than 5 percentage (%) blasts in aspirate sample with marrow spicules and with a count of greater than or equal to (\>=) 200 nucleated cells, plus absolute neutrophil count (ANC) greater than (\>) 1,000/ microliter, platelet count of \>100,000/microliter and participant must be independent of transfusions for a minimum of 1 week before each marrow assessment.
Time frame: End of study treatment (approximately 3 years)
Phase 1 and 2: Maximum Plasma Concentration (Cmax) of Decitabine
Cmax is the maximum observed plasma concentration of Decitabine.
Time frame: Cycle 1 (28 days) Day 5: pre-infusion, 0.5 hour during infusion, end of infusion and at 5 min, 0.5 hour, 1 hour, and 2 hour after end of infusion
Phase 1 and 2: Area Under the Plasma Concentration-Time Curve (AUC) of Decitabine
AUC is the area under the plasma concentration-time curve of decitabine.
Time frame: Cycle 1 (28 days) Day 5: pre-infusion, 0.5 hour during infusion, end of infusion and at 5 min, 0.5 hour, 1 hour, and 2 hour after end of infusion
Phase 2: Duration of Response
Duration of response is defined as weeks from date of first response to date of first relapse or date of death.
Time frame: From time of response to relapse, study completion/withdrawal, or death, whichever comes first, for up to approximately 3 years 10 months
Phase 2: Overall Response Rate
Overall response rate is defined as percentage of participants with complete remission (CR) +complete remission with incomplete blood count recovery (CRi)+partial remission (PR) per IWG Criteria. CRi: morphologic CR with residual neutropenia (less than \[\<\] 1,000/microliter) or thrombocytopenia \<100,000/microliter). CR is defined as morphologic leukemia-free state, with less than 5 percentage (%) blasts in aspirate sample with marrow spicules and with a count of greater than or equal to (\>=) 200 nucleated cells, plus absolute neutrophil count (ANC) greater than (\>) 1,000/ microliter platelet count of \>100,000/microliter and participant must be independent of transfusions for a minimum of 1 week before each marrow assessment. PR: all the same hematologic values of a CR, but with a decrease of \>=50% of the percentage of blasts to 5% to 25% in the bone marrow aspirate.
Time frame: Up to approximately 3 years 10 months
Phase 1 and 2: Overall Survival (OS)
OS is defined as the time from the date of first dose of study drug to date of death from any cause. If the participant is alive or the vital status is unknown, the participant will be censored at the date the participant will be last known to be alive.
Time frame: From enrollment to death or withdrawal, whichever comes first, for up to approximately 3 years 10 months
Phase 1 and 2: Event-Free Survival
Event free survival is defined as the time from first dose of study drug to relapse from CR, death, or second malignancy for participants who achieved CR. CR is defined as morphologic leukemia-free state, with less than 5 percentage (%) blasts in aspirate sample with marrow spicules and with a count of greater than or equal to (\>=) 200 nucleated cells, plus absolute neutrophil count (ANC) greater than (\>) 1,000/ microliter platelet count of \>100,000/microliter and participant must be independent of transfusions for a minimum of 1 week before each marrow assessment.
Time frame: From enrollment to progression/relapse, death, or withdrawal, whichever comes first, for up to approximately 3 years 10 months
Phase 1 and 2: Number of Participants Reporting Treatment-Emergent Adverse Events (TEAEs)
TEAEs are defined as adverse events with onset or worsening on or after date of first dose of study treatment. An adverse event is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product.
Time frame: Approximately 3 years 10 months
| Milestone | Cohort 1: Decitabine 20 mg/m^2 + Cytarabine 1 g/m^2 | Cohort 2: Decitabine 20 mg/m^2 + Cytarabine 2 g/m^2 |
|---|---|---|
| Started | 9 | 7 |
| Completed | 0 | 7 |
| Not completed | 9 | 0 |
| Withdrew: Lack of efficacy | 8 | 0 |
| Withdrew: Other | 1 | 0 |
| Milestone | Cohort 1: Decitabine 20 mg/m^2 + Cytarabine 1 g/m^2 | Cohort 2: Decitabine 20 mg/m^2 + Cytarabine 2 g/m^2 |
|---|---|---|
| Started | 0 | 8 |
| Completed | 0 | 0 |
| Not completed | 0 | 8 |
| Withdrew: Physician decision | 0 | 1 |
| Withdrew: Proceed to transplant | 0 | 3 |
| Withdrew: Lack of efficacy | 0 | 4 |
The maximum tolerated dose (MTD) for cytarabine was based on the number of participants experiencing a dose-limiting toxicity (DLT) by the end of Cycle 1. A non-hematological DLT was defined as: any Grade \>=3 toxicity that persists for greater than (\>) 5 days or any Grade 2 toxicity that persists for \>7 days and that is intolerable to the participant. A hematological DLT was defined as Grade 4 neutropenia or thrombocytopenia due to a hypoplastic bone marrow at Day 42, in the absence of malignant infiltration. The nominal duration of each cycle was 28 days. However, participants who had not experienced bone marrow recovery at Day 28 were followed up to Day 42. Failure of marrow recovery (improvement to Grade 3) by Day 42 was considered a DLT. The maximum duration of Cycle 1 was therefore 42 days.
| gram per square meter | Decitabine (Dacogen) + Cytarabine |
|---|---|
| Phase 1: Maximum Tolerated Dose (MTD) of Cytarabine | 2 |
Cmax is the maximum observed plasma concentration of Decitabine.
| nanogram per milliliter (ng/mL) | Decitabine (Dacogen) + Cytarabine |
|---|---|
| > 1 month to <= 2 years | 118.4 (17.6 to 1621) |
| > 2 to <= 6 years | 123.1 (15.6 to 1012) |
| > 6 to <= 12 years | 148.7 (16.5 to 1415) |
| > 12 to <= 16 years | 151.4 (19.1 to 1303) |
Total clearance of drug after intravenously administration was calculated as: dose/area under the plasma concentration-time curve.
| liter per hour per square meter | Decitabine (Dacogen) + Cytarabine |
|---|---|
| >1 month to less than or equal to (<=) 2 years | 160.6 (11.7 to 942.3) |
| Greater than (>) 2 to <= 6 years | 152.1 (19.5 to 1061) |
| > 6 to <= 12 years | 125.9 (13.3 to 951.3) |
| > 12 to <= 16 years | 123.2 (11.4 to 832.6) |
AUC is the area under the plasma concentration-time curve of decitabine.
| nanogram*hour per milliliter (ng*h/mL) | Decitabine (Dacogen) + Cytarabine |
|---|---|
| > 1 month to <= 2 years | 124.8 (21.3 to 1708) |
| > 2 to <= 6 years | 131.5 (19.3 to 1028) |
| > 6 to <= 12 years | 158.9 (21.0 to 1508) |
| > 12 to <= 16 years | 162.4 (24.2 to 1747) |
Duration of response is defined as weeks from date of first response to date of first relapse or date of death.
| weeks | Decitabine (Dacogen) + Cytarabine |
|---|---|
| Participant 1 | 44.6 |
| Participant 2 | 6.3 |
Overall response rate is defined as percentage of participants with complete remission (CR) +complete remission with incomplete blood count recovery (CRi)+partial remission (PR) per IWG Criteria. CRi: morphologic CR with residual neutropenia (less than \[\<\] 1,000/microliter) or thrombocytopenia \<100,000/microliter). CR is defined as morphologic leukemia-free state, with less than 5 percentage (%) blasts in aspirate sample with marrow spicules and with a count of greater than or equal to (\>=) 200 nucleated cells, plus absolute neutrophil count (ANC) greater than (\>) 1,000/ microliter platelet count of \>100,000/microliter and participant must be independent of transfusions for a minimum of 1 week before each marrow assessment. PR: all the same hematologic values of a CR, but with a decrease of \>=50% of the percentage of blasts to 5% to 25% in the bone marrow aspirate.
| Percentage of participants | Decitabine (Dacogen) + Cytarabine |
|---|---|
| Phase 2: Overall Response Rate | 37.5 |
OS is defined as the time from the date of first dose of study drug to date of death from any cause. If the participant is alive or the vital status is unknown, the participant will be censored at the date the participant will be last known to be alive.
| months | Decitabine (Dacogen) + Cytarabine |
|---|---|
| Phase 1 and 2: Overall Survival (OS) | 5.1 (3.1 to 11.4) |
Event free survival is defined as the time from first dose of study drug to relapse from CR, death, or second malignancy for participants who achieved CR. CR is defined as morphologic leukemia-free state, with less than 5 percentage (%) blasts in aspirate sample with marrow spicules and with a count of greater than or equal to (\>=) 200 nucleated cells, plus absolute neutrophil count (ANC) greater than (\>) 1,000/ microliter platelet count of \>100,000/microliter and participant must be independent of transfusions for a minimum of 1 week before each marrow assessment.
| days | Decitabine (Dacogen) + Cytarabine |
|---|---|
| Phase 1 and 2: Event-Free Survival | 1 (1 to 348) |
TEAEs are defined as adverse events with onset or worsening on or after date of first dose of study treatment. An adverse event is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product.
| Participants | Decitabine (Dacogen) + Cytarabine |
|---|---|
| Phase 1 and 2: Number of Participants Reporting Treatment-Emergent Adverse Events (TEAEs) | 17 |
Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug.
| liter per square meter | Decitabine (Dacogen) + Cytarabine |
|---|---|
| > 1 month to <= 2 years | 35.9 (2.7 to 558.4) |
| > 2 to <= 6 years | 36.5 (1.4 to 535.0) |
| > 6 to <= 12 years | 31.8 (2.0 to 645.8) |
| > 12 to <= 16 years | 35.9 (2.8 to 578.9) |
Response rate (percentage of participants who achieved CR or CRi) was measured using international working group (IWG) criteria. Response rate is defined as complete remission (CR) or complete remission with incomplete blood count recovery (CRi) in children with relapsed or refractory acute myeloid leukemia. CRi is defined as morphologic CR with residual neutropenia (less than \[\<\] 1,000/microliter) or thrombocytopenia \<100,000/ microliter). CR is defined as morphologic leukemia-free state, with less than 5 percentage (%) blasts in aspirate sample with marrow spicules and with a count of greater than or equal to (\>=) 200 nucleated cells, plus absolute neutrophil count (ANC) greater than (\>) 1,000/ microliter, platelet count of \>100,000/microliter and participant must be independent of transfusions for a minimum of 1 week before each marrow assessment.
| percentage of participants | Decitabine (Dacogen) + Cytarabine |
|---|---|
| Phase 2: Percentage of Participants Who Achieved CR or CRi at Cycle 1 Day 28 | 20 |
Response rate (percentage of participants who achieved CR or CRi) was measured using international working group (IWG) criteria. Response rate is defined as complete remission (CR) or complete remission with incomplete blood count recovery (CRi) in children with relapsed or refractory acute myeloid leukemia. CRi is defined as morphologic CR with residual neutropenia (less than \[\<\] 1,000/microliter) or thrombocytopenia \<100,000/ microliter). CR is defined as morphologic leukemia-free state, with less than 5 percentage (%) blasts in aspirate sample with marrow spicules and with a count of greater than or equal to (\>=) 200 nucleated cells, plus absolute neutrophil count (ANC) greater than (\>) 1,000/ microliter, platelet count of \>100,000/microliter and participant must be independent of transfusions for a minimum of 1 week before each marrow assessment.
| percentage of participants | Decitabine (Dacogen) + Cytarabine |
|---|---|
| Phase 2: Percentage of Participants Who Achieved CR or CRi at Cycle 2 Day 28 | 66.7 |
Response rate (percentage of participants who achieved CR or CRi) was measured using international working group (IWG) criteria. Response rate is defined as complete remission (CR) or complete remission with incomplete blood count recovery (CRi) in children with relapsed or refractory acute myeloid leukemia. CRi is defined as morphologic CR with residual neutropenia (less than \[\<\] 1,000/microliter) or thrombocytopenia \<100,000/ microliter). CR is defined as morphologic leukemia-free state, with less than 5 percentage (%) blasts in aspirate sample with marrow spicules and with a count of greater than or equal to (\>=) 200 nucleated cells, plus absolute neutrophil count (ANC) greater than (\>) 1,000/ microliter, platelet count of \>100,000/microliter and participant must be independent of transfusions for a minimum of 1 week before each marrow assessment.
| percentage of participants | Decitabine (Dacogen) + Cytarabine |
|---|---|
| Phase 2: Percentage of Participants Who Achieved CR or CRi at End of Study Treatment | 12.5 |
Collected over Screening up to end of study (approximately 3 years 10 months). Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Phase 1 (Cohort 1): Dacogen + Cytarabine | 8/9 (88.9%) | 4/9 (44.4%) | 9/9 (100%) |
| Phase 1 (Cohort 2) and Phase 2: Dacogen + Cytarabine | 6/8 (75%) | 4/8 (50%) | 8/8 (100%) |
| Event | Phase 1 (Cohort 1): Dacogen + Cytarabine | Phase 1 (Cohort 2) and Phase 2: Dacogen + Cytarabine |
|---|---|---|
| Febrile NeutropeniaBlood and lymphatic system disorders | 3/9 | 2/8 |
| SepsisInfections and infestations | 0/9 | 2/8 |
| AnaemiaBlood and lymphatic system disorders | 0/9 | 1/8 |
| NeutropeniaBlood and lymphatic system disorders | 0/9 | 1/8 |
| ThrombocytopeniaBlood and lymphatic system disorders | 0/9 | 1/8 |
| KeratitisEye disorders | 0/9 | 1/8 |
| PyrexiaGeneral disorders | 1/9 | 1/8 |
| Lung InfectionInfections and infestations | 0/9 | 1/8 |
| Complication Associated with DeviceGeneral disorders | 1/9 | 0/8 |
| Skin ExfoliationSkin and subcutaneous tissue disorders | 1/9 | 0/8 |
| Event | Phase 1 (Cohort 1): Dacogen + Cytarabine | Phase 1 (Cohort 2) and Phase 2: Dacogen + Cytarabine |
|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 6/9 | 8/8 |
| PyrexiaGeneral disorders | 2/9 | 6/8 |
| ThrombocytopeniaBlood and lymphatic system disorders | 6/9 | 4/8 |
| LeukopeniaBlood and lymphatic system disorders | 1/9 | 5/8 |
| VomitingGastrointestinal disorders | 4/9 | 5/8 |
| Febrile NeutropeniaBlood and lymphatic system disorders | 5/9 | 0/8 |
| NeutropeniaBlood and lymphatic system disorders | 2/9 | 4/8 |
| StomatitisGastrointestinal disorders | 1/9 | 3/8 |
| HypokalaemiaMetabolism and nutrition disorders | 3/9 | 3/8 |
| DiarrhoeaGastrointestinal disorders | 3/9 | 2/8 |
Population included all enrolled participants in Phase 1 and Phase 2.
| Age, Continuous(months) | Dacogen + Cytarabine |
|---|---|
| Mean | 73.3 ± 46.26 |
| Sex: Female, Male(Participants) | Dacogen + Cytarabine |
|---|---|
| Female | 4 |
| Male | 13 |
| Ethnicity (NIH/OMB)(Participants) | Dacogen + Cytarabine |
|---|---|
| Hispanic or Latino | 2 |
| Not Hispanic or Latino | 10 |
| Unknown or Not Reported | 5 |
| Race (NIH/OMB)(Participants) | Dacogen + Cytarabine |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 1 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 2 |
| White | 8 |
| More than one race | 1 |
| Unknown or Not Reported | 5 |
| Region of Enrollment(Participants) | Dacogen + Cytarabine |
|---|---|
| Belgium | 1 |
| Denmark | 2 |
| France | 4 |
| Germany | 1 |
| Netherlands | 1 |
| Spain | 4 |
| United Kingdom | 4 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Oct 2013 to primary completion in Aug 2017, 46 months.
Results were first posted in Jun 2019, 1 year 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Decitabine
Janssen Research & Development, LLC →